62.6 F
New York
Friday, May 7, 2021

Russia’s R-Pharm Signs Deal With AstraZeneca [NYSE: AZN] To Develop COVID-19 Vaccine

Must read

Coinbase Pro Announces it will be Listing Internet Computer’s ICP

Coinbase Pro cryptocurrency exchange has disclosed that it has decided to list ICP once it goes live. ICP is the governance token of the...

WISeKey [NASDAQ: WKEY] Gets Investment to finance its TrustNFT.IO NFT Platform

WISeKey International Holding AG disclosed Friday that it has inked a term-sheet to enter into an unsecured short-term loan and the issuance and...

Moderna [NASDAQ: MRNA] Inks Supply Agreement with Switzerland

Moderna, Inc. disclosed that it has inked a supply agreement on Thursday with the Swiss Federal Government. As per the agreement, Moderna Inc...

TeraBlock Will Have its Own BSCPad IDO Soon

TeraBlock which is a project making a platform for automated cryptocurrency portfolio management disclosed that it is preparing for an initial DEX offering (IDO)...

Russian drugmaker R-Pharm has made a deal with a drug maker AstraZeneca to develop a coronavirus vaccine. It has disclosed on Friday that both the companies have signed the contract for the manufacturing of the COVID-19 vaccine which is being developed by the British pharmaceutical giant and Oxford University.

Canada, the US, and Britain earlier accused Russia that it is trying to steal the COVID-19 vaccine and treatment research. But after the deal, Russia’s wealth fund disclosed that Moscow has no need to steal information.

Shares of AstraZeneca soared 1.11% at $58.07 during the trading of Friday. It has a trading volume of 4.89 million as compared to the average volume of 5.41 million. In the past 52-weeks of trading, it has fluctuated between a low of 36.15 and a high of 58.84.

If we turn our focus on the profitability, it has reurn on investment (ROI) of 8.30%, return on equity (ROE) of 12.30% and return on assets (ROA) of 2.50%. This company has Gross Margin of 79.60%, and an Operating Margin of 12.10%, Profit Margin of 6.00%.

Alexey Repik, chairman of the R-Pharm Board said: “We have formalized the project in the area of signed agreements in the field of vaccine development and supply, developed by AstraZeneca and Oxford University.” R-Pharm specializes in research and development and manufacturing of high-tech medicines.

More articles

Latest article

Why Chiasma [NASDAQ: CHMA] Stock is Skyrocketed?

Shares of Chiasma, Inc. surged 46.48% during the trading session of Wednesday. Chiasma has disclosed the financial results for the Q1 completed March...

NeoGenomics [NASDAQ: NEO] Announces Acquisition of Inivata Ltd

NeoGenomics, Inc. revealed Wednesday that it has decided to purchase Inivata Ltd. Inivata will grow into a liquid biopsy-centered division together with increasing...

R1 RCM [NASDAQ: RCM] Announces Acquisition of VisitPay

R1 RCM Inc. disclosed Tuesday that it has decided to purchase VisitPay. The firm has inked an agreement to buy VisitPay for nearly...

Binance Coin Makes History as its Market Cap Reach $100 Billion

The market capitalization of Binance set new records as the exchange token of Binance and the native asset of Binance Smart Chain (BSC) touched...

Precipio [NASDAQ: PRPO] Roll Out Rapid COVID-19 Antibody test on Amazon Platform

Shares of Precipio, Inc. skyrocketed 40.35% during the trading session of Monday. The strong performance of the firm has highlighted the positive sentiments...

TechX Ink Deal to Buy Fiat-to-Crypto Merchant Services Gateway XPort Digital

TechX Technologies Inc disclosed Monday that it has bought fiat-to-crypto merchant services gateway XPort digital. The firm has bought a 100% stake in XPort...

Lockheed [NYSE: LMT] Present F-35 Best and Final Offer to Finnish Government

Lockheed Martin Corporation disclosed that it has presented F-35 best and final offer (BAFO) on April 29, 2021, to the Finnish government. It...

Clene [NASDAQ: CLNN] Gets Two Patent Notice of Allowances

Clene Inc. disclosed that Clene Nanomedicine, Inc. U.S. Patent and Trademark Office has provided Notices of Allowance for two significant patent applications. Clene...